SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 2
    Curran W, Scott C, Langer C, et al. Long term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable NSCLC: RTOG 9410 [abstract]. Proc Am Soc Clin Oncol. 2003; 22:621a.
  • 3
    Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17: 2692-2699.
  • 4
    Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study. J Clin Oncol. 2005; 23: 5910-5917.
  • 5
    Socinski M, Rosenman J, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small-cell lung carcinoma. Cancer. 2001; 92: 1213-1223.
  • 6
    Schild S, McGinnis W, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1106-1111.
  • 7
    Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using 3-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol. 2010; 28: 2475-2480.
  • 8
    Moyers MF, Miller DW, Bush DA, et al. Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys. 2001; 49: 1429-1438.
  • 9
    Chang J, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with 3-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1087-1096.
  • 10
    Chang JY, Dong L, Liu H, et al. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008; 3: 177-186.
  • 11
    Kang Y, Zhang X, Chang JY, et al. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys. 2007; 67: 906-914.
  • 12
    Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. [published online ahead of print January 24, 2011.]
  • 13
    Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early stage medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. [published online ahead of print January 18, 2011.]
  • 14
    Shioyama Y, Tokuuye K, Okumura T, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003; 56: 7-13.
  • 15
    Nakayama H, Satoh H, Sugahara S, et al. Proton beam therapy of stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. [published online ahead of print September 30, 2010.]
  • 16
    Bush D. Proton radiation therapy for lung cancer: is there enough evidence? Oncology. 2010; 24: 1052-1057.
  • 17
    Kepka L, Maciejewski B, Withers RH. Does incidental irradiation with doses below 50 Gy effectively reduce isolated nodal failures in non-small-cell lung cancer: dose-response relationship. Int J Radiat Oncol Biol Phys. 2009; 73: 1391-1396.
  • 18
    Engelsman M, Rietzel E, Kooy HM. Four-dimensional proton treatment planning for lung tumors. Int J Radiat Oncol Biol Phys. 2006; 64: 1589-1595.
  • 19
    Hui Z, Zhang X, Starkschall G, et al. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 1385-1395.
  • 20
    Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces normal tissue doses compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB-non-small cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010; 77: 357-366.